SG11202113119QA - Compositions and methods for thymic regeneration and t-cell reconstitution - Google Patents

Compositions and methods for thymic regeneration and t-cell reconstitution

Info

Publication number
SG11202113119QA
SG11202113119QA SG11202113119QA SG11202113119QA SG11202113119QA SG 11202113119Q A SG11202113119Q A SG 11202113119QA SG 11202113119Q A SG11202113119Q A SG 11202113119QA SG 11202113119Q A SG11202113119Q A SG 11202113119QA SG 11202113119Q A SG11202113119Q A SG 11202113119QA
Authority
SG
Singapore
Prior art keywords
ntecs
cells
thymic
subject
bmp4
Prior art date
Application number
SG11202113119QA
Other languages
English (en)
Inventor
Paul Finnegan
Daniel Nolan
Karolina Kucharova
Michael Ginsberg
Kenneth Wills
Original Assignee
Angiocrine Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiocrine Bioscience Inc filed Critical Angiocrine Bioscience Inc
Publication of SG11202113119QA publication Critical patent/SG11202113119QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202113119QA 2019-05-28 2020-05-28 Compositions and methods for thymic regeneration and t-cell reconstitution SG11202113119QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853452P 2019-05-28 2019-05-28
PCT/US2020/034932 WO2020243310A1 (en) 2019-05-28 2020-05-28 Compositions and methods for thymic regeneration and t-cell reconstitution

Publications (1)

Publication Number Publication Date
SG11202113119QA true SG11202113119QA (en) 2021-12-30

Family

ID=73553922

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113119QA SG11202113119QA (en) 2019-05-28 2020-05-28 Compositions and methods for thymic regeneration and t-cell reconstitution

Country Status (10)

Country Link
US (1) US20220226391A1 (https=)
EP (1) EP3976065A4 (https=)
JP (1) JP7637418B2 (https=)
KR (1) KR20220015451A (https=)
CN (1) CN114340642A (https=)
AU (1) AU2020283586A1 (https=)
CA (1) CA3141989A1 (https=)
IL (1) IL288439A (https=)
SG (1) SG11202113119QA (https=)
WO (1) WO2020243310A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753441C2 (ru) 2016-09-13 2021-08-16 Ангиокрин Биосайенс, Инк. Гематоэнцефалический барьер, содержащий сконструированные эндотелиальные клетки
WO2024155791A1 (en) * 2023-01-18 2024-07-25 Angiocrine Bioscience, Inc. Use of umbilical vein endothelial cells for the treatment of lung injury
WO2025245461A1 (en) * 2024-05-23 2025-11-27 Thymofox Inc. Methods of activating foxn1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465732B2 (en) * 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
WO2016069911A1 (en) * 2014-10-29 2016-05-06 Jarrod Dudakov Use of bmp4 for thymic regeneration
RU2743761C2 (ru) 2014-12-19 2021-02-25 Анджиокрин Биосайенс, Инк. Биосовместимые имплантаты, содержащие сконструированные эндотелиальные клетки
RU2753441C2 (ru) * 2016-09-13 2021-08-16 Ангиокрин Биосайенс, Инк. Гематоэнцефалический барьер, содержащий сконструированные эндотелиальные клетки

Also Published As

Publication number Publication date
EP3976065A1 (en) 2022-04-06
JP7637418B2 (ja) 2025-02-28
US20220226391A1 (en) 2022-07-21
IL288439A (en) 2022-01-01
KR20220015451A (ko) 2022-02-08
AU2020283586A1 (en) 2021-12-23
CA3141989A1 (en) 2020-12-03
JP2022534586A (ja) 2022-08-02
CN114340642A (zh) 2022-04-12
WO2020243310A1 (en) 2020-12-03
EP3976065A4 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
US12486327B2 (en) CAR for use in the treatment of HvG disease
AU2016297524B2 (en) Engineered endothelial cells expressing an ets transcription factor
TW201736594A (zh) 抗原特異性ｔｃｒ的新生成
JP7637418B2 (ja) 胸腺再生およびｔ細胞再構成のための組成物および方法
US9592259B2 (en) APC-mediated tolerance induction for therapy of multiple sclerosis
EA010434B1 (ru) Способ получения цитотоксических лимфоцитов
JP2022522231A (ja) 抗ｂｃｍａ ｃａｒ ｔ細胞の製造
JP2022541293A (ja) がん細胞療法用のｐ２１発現単球
US20180085398A1 (en) Compositions and methods of treating cancer
Jung et al. Stimulatory effect of HGF‐overexpressing adipose tissue‐derived mesenchymal stem cells on thymus regeneration in a rat thymus involution model
US20210317410A1 (en) Methods of making natural killer cells and uses thereof
US20070196335A1 (en) Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells
Sonderbye et al. In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction
US20090215875A1 (en) Methods and kits for expanding hematopoietic stem cells
EP1697503B1 (en) Cell culture with nm23, cell culture media comprising nm23 and therapeutic use of cells cultured in the presence of nm23
Nayak et al. Modulation of renal carcinoma cells in vitro: Comparison after transduction with retroviral vector containing a human IFN-gamma gene versus incubation with soluble IFN-gamma
US20240018482A1 (en) Cryopreserved endothelial cell compositions
US20230414720A1 (en) Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
Winterhalter CRISPR/Cas9 based HLA reduction of T cells for universal T cell therapy
WO2023122099A2 (en) Crispr-based gene editing to preserve splicing and expression of foxp3 isoforms 1 and 2